FDA Brief

Warning letters Drugs

FDA warning letter to

Intas Pharmaceuticals Limited

Issued Nov 21, 2023Posted Nov 28, 2023Center for Drug Evaluation and Research | CDER

CGMP/Finished Pharmaceuticals/Adulterated. We haven't summarized this letter yet. Read it on fda.gov.

Intas Pharmaceuticals Limited's FDA history

  1. Intas Pharmaceuticals Limited

    FDA warns Intas Pharmaceuticals' Dehradun, India plant over weak out-of-spec investigations and untracked batch-record edits for its tablets.

    High risk
  2. Intas Pharmaceuticals Limited

    FDA warned Intas Pharmaceuticals about serious manufacturing-quality violations, including data integrity failures and inaccurate environmental monitoring, at its India drug plant.

    High risk

Full company page